Xin Lang Cai Jing·2025-09-21 09:20Core Points - A laboratory accident at Kanglong Chemical resulted in the death of two employees due to asphyxiation, which occurred on June 3, 2023 [1][2] - The incident involved the production of an innovative drug, DT-818, which is currently in the IND approval stage and requires strict oxygen control during its production process [1][2] - The investigation revealed that the deceased employees failed to follow safety protocols, specifically not using the flexible isolator gloves as required [2] Company Responsibility - The report identified nine responsible individuals, including the main leader, who failed to fulfill safety oversight duties, leading to the accident [2] - Recommendations for penalties include a fine of 40% of the annual income for the main responsible person and fines ranging from 20% to 50% of annual income for other executives [2] - Kanglong Chemical was found to have inadequate safety management practices, employee training, and risk control measures, which contributed to the incident [3] Financial Performance - For the first half of 2025, Kanglong Chemical reported revenue of 6.441 billion yuan, a year-on-year increase of 14.93%, with a quarter-on-quarter growth of 7.85% in Q2 [4] - The net profit attributable to shareholders was 701 million yuan, a decline of 37% year-on-year, while the net profit excluding non-recurring items increased by 36.66% [4] - The company secured new orders exceeding 10% year-on-year and served over 2,600 global clients, with significant revenue growth from the top 20 pharmaceutical companies [4]